Pfizer study estimates its vaccine helped prevent over 110,000 Covid deaths

Pfizer-BioNTech COVID-19 Vaccine contributed to averting almost 9 million symptomatic cases, close to 700,000 hospitalizations, and over 110,000 deaths --study

A combined Markov decision tree model compared clinical and economic outcomesof the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) versus no vaccination in individuals aged ≥12 years. Age-stratified epidemiological, clinical, economic, and humanistic parameters
were derived from existing data and published literature. Scenario analysis explored the impact of using lower and upper bounds of parameters on the results.

The health benefits were estimated as the number of COVID-19 symptomatic cases, hospitalizations and deaths averted, and Quality
Adjusted Life Years (QALYs) saved. The economic benefits were estimated as the amount of healthcare and societal cost savings associated with the vaccine-preventable health outcomes.

Results: It was estimated that, in 2021, the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)
contributed to averting almost 9 million symptomatic cases, close to 700,000 hospitalizations, and over 110,000 deaths, resulting in an estimated $30.4 billion direct healthcare cost savings,
$43.7 billion indirect cost savings related to productivity loss.

....